- Yasukawa, who brings more than 30 years of experience in the pharmaceutical industry, succeeds Yoshihiko Hatanaka, who will become Chairman of the Board -
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company” ) today announced that its Board of Directors approved a change in its Representative Director, President and CEO as stated below.
- Reason for Change
The changes below enable Astellas to vigorously pursue the new strategic plan, which is set to start in the fiscal year 2018, aiming to realize the Astellas’ Vision of being on the forefront of healthcare change to turn innovative science into value for patients.
- Changes of Representative Directors
- Effective date of change:
April 1, 2018
(Reference)
- Curriculum Vitae of new Representative Director, Chairman of the Board
Name: Yoshihiko Hatanaka
Date of Birth: April 20, 1957
Place of Birth: Shizuoka prefecture
-Career History
-Education- March 1980
- Hitotsubashi University Bachelor of Economics
- Curriculum Vitae of new Representative Director, Chairman of the Board
Name: Kenji Yasukawa
Date of Birth: June 7, 1960
Place of Birth: Tokyo
-Career History -Education- July 2001
- Showa University Graduate School of Pharmaceutical
- Sciences, Japan, Ph.D. in Pharmaceutical Sciences
- March 1986
- University of Tokyo, Master of Science, Agriculture
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
